

PRECEPTORSHIP PROGRAMME

Gastric Cancer

**ESMO
PRECEPTORSHIP**

**VALENCIA SPAIN
29-30 SEPTEMBER 2023**

Multidisciplinary management, standards of care, therapeutic targets and future perspectives.

Co-Chairs

Florian Lordick, Germany

Elizabeth Smyth, United Kingdom

ESMO PRECEPTORSHIP PROGRAMME GASTRIC CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Valencia, Spain
29-30 September 2023

CO-CHAIRS Florian Lordick, Germany
Elizabeth Smyth, United Kingdom

SPEAKERS Fátima Carneiro, Portugal
Tania Fleitas, Spain
Maria Hawkins, United Kingdom
Radka Obermannová, Czech Republic
Guillaume Piessen, France

LEARNING OBJECTIVES

- To learn about the fundamentals of epidemiology, aetiology, pathogenesis, molecular events and immune biology of gastric and esophago-gastric junction cancer
- To understand the essentials in the diagnosis and multidisciplinary treatment of gastric cancer
- To learn about advances in the treatment and novel targets in gastric cancer

ACCREDITATION

The programme of this event has been accredited with **10 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an independent educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 29 September 2023

09:00-09:10 10'	Opening and welcome	
10'	Welcome from ESMO and introduction	Florian Lordick, DE
09:10-11:10 120'	SESSION 1 Pathology and diagnosis of gastric cancer	Chair: Florian Lordick, DE
20'	Gastric cancer as a global problem	Tania Fleitas, ES
30'	Genomics and pathology of hereditary cancers	Fátima Carneiro, PT
40'	Clinically useful pathology biomarkers (with some genomics!)	Elizabeth Smyth, UK
30'	Discussion	Faculty
11:10-11:40	Coffee break	
11:40-13:20 100'	SESSION 2 Surgical, adjuvant and neoadjuvant treatment of gastric cancer	Chair: Elizabeth Smyth, UK
30'	Surgery for gastric and EG junction cancer, primary, palliative - Where and when?	Guillaume Piessen, FR
30'	Perioperative treatment for gastric cancer: State of the art and current controversies	Elizabeth Smyth, UK
20'	Radiation therapy for gastric cancer, and oesophago-gastric junction cancer	Maria Hawkins, UK
20'	Discussion	Faculty
13:20-14:20	Lunch	
14:20-15:00 40'	SESSION 3 Break-out session: Oesophageal cancer	Chairs: Maria Hawkins, UK Guillaume Piessen, FR
30'	Particular aspects in patients with squamous cell histology (peri-operative and advanced)	Radka Obermannová, CZ
10'	Discussion	Faculty
15:00-15:30	Coffee break	
15:30-17:20 110'	SESSION 4 Advanced disease	Chair: Elizabeth Smyth, UK
30'	Sequential chemotherapy (doublet, triplet, elderly patients, sequences, anti-angiogenic therapy, oral chemotherapy)	Tania Fleitas, ES
30'	Biologically targeted treatment (HER2, Claudin 18.2, FGFR2, and beyond)	Florian Lordick, DE
30'	Immunotherapy for advanced gastroesophageal adenocarcinoma	Elizabeth Smyth, UK
20'	Discussion	Faculty
20:30	Dinner	

Saturday, 30 September 2023

09:00-10:30 90'	SESSION 5 Case discussion based on ESMO Clinical Practice Guidelines I	Chair: Florian Lordick, DE
90'	Participants clinical case discussion (6x15')	Faculty
10:30-11:00	Coffee break	
11:00-12:30 90'	SESSION 6 Case discussion based on ESMO Clinical Practice Guidelines II	Chair: Elizabeth Smyth, UK
90'	Participants clinical case discussion (6x15')	Faculty
12:30-12:50 20'	Future outlook, conclusion and farewell	Florian Lordick, DE Elizabeth Smyth, UK
12:50-14:00	Lunch	

Note: Each 15-minute slot for clinical case discussion includes a 7' case presentation and an 8' Q&A / panel discussion